Jump to:
Ryan Kramer joined Ropes & Gray’s corporate department in 2022. Ryan primarily practices in the life sciences and intellectual property transactions groups, advising clients on a broad range of matters including complex licensing arrangements, collaborations, mergers & acquisitions, and royalty monetization transactions.
During law school, Ryan served as a notes editor for the Boston University Law Review and as a lawyering fellow in the school’s first-year legal writing program. He also served as the networking director for the Health Law Association and worked as a research assistant focusing on consumer protection and privacy law.
Experience
- Represented Sarepta Therapeutics in a transformational global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple siRNA programs worth up to $11.35 billion.
- Represented Novo Nordisk in a worldwide collaboration with Neomorph Inc. worth up to $1.46 billion to discover, develop and commercialize molecular glue degraders for multiple targets.
- Advised ImmunoGen, Inc. on intellectual property matters related to its $10.1 billion sale to AbbVie Inc.
- Represented Regeneron Pharmaceuticals in its acquisition of 2seventy Bio Inc.’s oncology and autoimmune programs as part of its newly launched R&D unit Regeneron Cell Medicines.
- Represented the lead underwriters in the initial public offering of Loar Holdings Inc.